Forte Biosciences (FBRX) Current Deferred Revenue (2016 - 2019)
Forte Biosciences (FBRX) posted quarterly Current Deferred Revenue of $9000.0 for Q3 2019, down 75.0% year-over-year from $36000.0 in Q3 2018, and down 50.0% quarter-over-quarter from $18000.0 in Q2 2019.
Powered by 
Analysis
Forte Biosciences (FBRX) Current Deferred Revenue (2016 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported Current Deferred Revenue for 4 consecutive years, with $9000.0 the latest figure, recorded in Q3 2019.
- In Q3 2019, Current Deferred Revenue fell 75.0% year-over-year to $9000.0; the TTM figure through Sep 2019 stood at $9000.0 (down 75.0% YoY), while the FY2018 annual figure was $36000.0, changed 0.0% from the prior year.
- Current Deferred Revenue slipped to $9000.0 in Q3 2019 per FBRX's latest filing, from $18000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.0 million in Q2 2018 and bottomed at $9000.0 in Q3 2019.
- Historically, Current Deferred Revenue has averaged $116833.3 across 4 years, with a median of $36000.0 in 2017.
- Annual changes were most pronounced in 2018 — Current Deferred Revenue soared 2426.83% — and 2019, when it plunged 98.26%.
- Forte Biosciences' Current Deferred Revenue stood at $45000.0 in 2016, then slipped by 20.0% to $36000.0 in 2017, then changed by 0.0% to $36000.0 in 2018, then slumped by 75.0% to $9000.0 in 2019.
- Business Quant data shows FBRX's Current Deferred Revenue at $9000.0 in Q3 2019, $18000.0 in Q2 2019, and $27000.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 9,000.00 |
| Jun 30, 2019 | 18,000.00 |
| Mar 31, 2019 | 27,000.00 |
| Dec 31, 2018 | 36,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Jun 30, 2018 | 1.04 Mn |
| Mar 31, 2018 | 36,000.00 |
| Dec 31, 2017 | 36,000.00 |
| Sep 30, 2017 | 41,000.00 |
| Jun 30, 2017 | 41,000.00 |
| Mar 31, 2017 | 41,000.00 |
| Dec 31, 2016 | 45,000.00 |